Sagimet Biosciences SGMT 深 滬
已收盤 02-06 16:00:00 美东时间
5.55
+0.110
+2.02%
華盛通- 最 高5.72
- 今 開5.58
- 成交量 77.23万股
- 最 低 5.365
- 昨 收 5.44
- 總市值 1.80亿
- 52周最高 11.41
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.73
- 委 比 54.44%
- 總股本 3252.16万
- 歷史最高 20.71
- 量 比 0.72
- 振 幅 6.53%
- 歷史最低 1.73
- 每 手 1
- 風險率 2.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks
BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks Feb 2 (Reuters) - Sagimet Biosciences Inc SGMT.O : SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASCLETIS’ OPEN-LABEL PHASE 3 CLINICAL TRIAL EVALUATING THE LONG-TERM SAFETY OF ASC40 (DENIFANSTAT) T
02-02 20:24
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Initiates Coverage On Sagimet Biosciences with Equal-Weight Rating, Announces Price Target of $8
Barclays analyst Eliana Merle initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Equal-Weight rating and announces Price Target of $8.
01-28 22:50
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Sagimet Biosciences will present a poster at the 10th Annual MASH-TAG Conference in Park City, Utah, on January 10, 2026. The presentation will highlight the anti-fibrotic effects of denifanstat, a FASN inhibitor, in F3 and qFibrosis stage 4 MASH patients from the Phase 2b FASCINATE-2 trial. Denifanstat showed significant improvement in fibrosis and biomarkers in these patients. MASH is a severe liver disease affecting over 265 million people, wi...
01-08 12:00
Sagimet Reports MASH Combo Data, Eyes Phase 2 for Liver Treatment
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive results in the Phase 1
2025-12-18 20:03
Sagimet Biosciences enters global license agreement with TAPI
Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an update. Sagimet ...
2025-12-17 20:28
Sagimet Biosciences Announced A License Agreement With A Subsidiary Of Teva Pharmaceutical
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports
2025-12-17 20:06
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
Sagimet Biosciences announced that China's NMPA has accepted the New Drug Application (NDA) for denifanstat, developed by Ascletis Pharma, to treat moderate to severe acne. Sagimet licensed denifanstat to Ascletis for China, while developing it for metabolic dysfunction-associated steatohepatitis (MASH) outside China. Denifanstat, as ASC40 in China, successfully met all endpoints in Phase 3 trials for acne. Sagimet is also exploring denifanstat i...
2025-12-10 12:03
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Inc. has granted 42,800 stock options to three new employees under Nasdaq Rule 5635(c)(4). The options, with an exercise price based on the December 9, 2025, closing price, vest over four years and have a ten-year term. Sagimet, a clinical-stage biopharmaceutical company, focuses on developing FASN inhibitors targeting metabolic and fibrotic pathways. Its lead product, denifanstat, met Phase 2b and Phase 3 endpoints in metabol...
2025-12-09 21:05
